Fig. 7: Deletion of bone marrow cell MLCK210 inhibits tumor growth.

a Schematic of bone marrow transplantation and tumor implantation. b Genomic PCR to detect Mlck210 gene in peripheral blood cells from BMT transplanted mice (n = 2 mice). c–e Tumor volumes (c), weights at endpoint (15 days) (*p < 0.0001 WT vs Mlck210^−/− BM) (d) and images of gross tumor morphology (e) from LLC tumors in WT mice transplanted with bone marrow from WT (n = 10 mice) or Mlck210^−/− mice (n = 10 mice). f Representative FACS profiles and g quantification of Gr1-CD11b+ (p = 0.9724) Gr1loCD11b+ (*p = 0.0280), Gr1hiCD11b+ (p = 0.8641) myeloid cells in representative WT vs Mlck210^−/− BM transplanted tumors harvested at endpoint (15 days) (n = 3 mice). For Facs gating scheme, see Supplementary Fig. 7b. h Representative histographs and i quantification of F4/80+ macrophages/field (n = sections from 5 WT mice and 5 Mlck210^−/−) *p = 0.0009, CD31+ blood vessels/field (n = sections from 5 WT and 3 Mlck210^−/− mice) *p = 0.001, CD8+ T cells/field (n = sections from 5 WT and 4 Mlck210^−/− mice) *p = 0.019 in tumor sections and 100X H&E-stained tumor sections to detect percent necrosis/field (n = sections from 5 mice) *p = 0.0004 from mice transplanted with WT vs Mlck210^−/− bone marrow. Data are presented as mean values ± SEM. Significance testing was performed by Student’s t-test. Experiments were performed twice. Source data are provided with this article as a Source Data file.